瑞舒伐他汀对凝血因子和同型半胱氨酸水平的影响能否降低高胆固醇血症患者的血栓风险?

Mostafa Behnam, Mohammad Reza Deyhim, Parichehreh Yaghmaei
{"title":"瑞舒伐他汀对凝血因子和同型半胱氨酸水平的影响能否降低高胆固醇血症患者的血栓风险?","authors":"Mostafa Behnam, Mohammad Reza Deyhim, Parichehreh Yaghmaei","doi":"10.2174/0118715257279903231205110750","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Hypercholesterolemia is one of the main risk factors for vascular thrombosis in individuals. Therefore, the use of statins is very effective in reducing cholesterol and can reduce the risk of thrombosis in these patients. Rosuvastatin, a member of the statin family which, inhibits cholesterol synthesis. Very few studies have been done in relation to how rosuvastatin can affect thrombosis. So, this research has been tried whether rosuvastatin can have an effect on coagulation factors and homocysteine as risk factors for thrombosis in hypercholesterolemia?</p><p><strong>Methods: </strong>In this experimental study, 60 patients (30 men and 30 women with a mean age of 40- 70 years) diagnosed with hypercholesterolemia (cholesterol > 250 mg/dl) participated in this research. 30 patients were prescribed rosuvastatin (20 mg/day), and 30 patients were simultaneously taken placebo for three months. All parameters, including FVIII, FV, Fibrinogen, DDimer, plasma homocysteine level and lipid profile, were measured before and after treatment. All the results were statistically compared between the two groups.</p><p><strong>Results: </strong>In patients who took rosuvastatin, the drug was able to significantly reduce the concentrations of total cholesterol, triglycerides, and low-density lipoprotein (LDL) (P < 0.001). Also, rosuvastatin was able to reduce the concentrations of homocysteine significantly, D-Dimer (P < 0.001), coagulation factor VIII and factor V (P < 0.05). In patients with hypercholesterolemia who took the placebo, did not affect the mentioned variables (P > 0.05).</p><p><strong>Conclusion: </strong>According to the results, it seems that rosuvastatin may be able to reduce the risk of thrombosis in patients by affecting coagulation factors and homocysteine levels.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can Rosuvastatin Reduce the Risk of Thrombosis in Patients with Hypercholesterolemia with its Effect on Coagulation Factors and Homocysteine Levels?\",\"authors\":\"Mostafa Behnam, Mohammad Reza Deyhim, Parichehreh Yaghmaei\",\"doi\":\"10.2174/0118715257279903231205110750\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Hypercholesterolemia is one of the main risk factors for vascular thrombosis in individuals. Therefore, the use of statins is very effective in reducing cholesterol and can reduce the risk of thrombosis in these patients. Rosuvastatin, a member of the statin family which, inhibits cholesterol synthesis. Very few studies have been done in relation to how rosuvastatin can affect thrombosis. So, this research has been tried whether rosuvastatin can have an effect on coagulation factors and homocysteine as risk factors for thrombosis in hypercholesterolemia?</p><p><strong>Methods: </strong>In this experimental study, 60 patients (30 men and 30 women with a mean age of 40- 70 years) diagnosed with hypercholesterolemia (cholesterol > 250 mg/dl) participated in this research. 30 patients were prescribed rosuvastatin (20 mg/day), and 30 patients were simultaneously taken placebo for three months. All parameters, including FVIII, FV, Fibrinogen, DDimer, plasma homocysteine level and lipid profile, were measured before and after treatment. All the results were statistically compared between the two groups.</p><p><strong>Results: </strong>In patients who took rosuvastatin, the drug was able to significantly reduce the concentrations of total cholesterol, triglycerides, and low-density lipoprotein (LDL) (P < 0.001). Also, rosuvastatin was able to reduce the concentrations of homocysteine significantly, D-Dimer (P < 0.001), coagulation factor VIII and factor V (P < 0.05). In patients with hypercholesterolemia who took the placebo, did not affect the mentioned variables (P > 0.05).</p><p><strong>Conclusion: </strong>According to the results, it seems that rosuvastatin may be able to reduce the risk of thrombosis in patients by affecting coagulation factors and homocysteine levels.</p>\",\"PeriodicalId\":93924,\"journal\":{\"name\":\"Cardiovascular & hematological agents in medicinal chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular & hematological agents in medicinal chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0118715257279903231205110750\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715257279903231205110750","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:高胆固醇血症是导致血管血栓形成的主要危险因素之一。因此,使用他汀类药物能有效降低胆固醇,减少这些患者的血栓风险。瑞舒伐他汀是他汀类药物家族中的一员,它能抑制胆固醇的合成。关于瑞舒伐他汀如何影响血栓形成的研究很少。因此,本研究试图探讨罗伐他汀是否会对作为高胆固醇血症血栓形成危险因素的凝血因子和同型半胱氨酸产生影响?在这项实验研究中,60 名确诊为高胆固醇血症(胆固醇大于 250 毫克/分升)的患者(30 名男性和 30 名女性,平均年龄 40-70 岁)参与了研究。30 名患者服用罗伐他汀(20 毫克/天),30 名患者同时服用安慰剂三个月。在治疗前后测量了所有参数,包括 FVIII、FV、纤维蛋白原、D-二聚体、血浆同型半胱氨酸水平和血脂概况。对两组患者的所有结果进行统计比较:结果:服用罗伐他汀的患者,总胆固醇、甘油三酯、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)的浓度明显降低(P 0.05):根据研究结果,洛伐他汀似乎可以通过影响凝血因子和同型半胱氨酸水平来降低患者血栓形成的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Can Rosuvastatin Reduce the Risk of Thrombosis in Patients with Hypercholesterolemia with its Effect on Coagulation Factors and Homocysteine Levels?

Background and objectives: Hypercholesterolemia is one of the main risk factors for vascular thrombosis in individuals. Therefore, the use of statins is very effective in reducing cholesterol and can reduce the risk of thrombosis in these patients. Rosuvastatin, a member of the statin family which, inhibits cholesterol synthesis. Very few studies have been done in relation to how rosuvastatin can affect thrombosis. So, this research has been tried whether rosuvastatin can have an effect on coagulation factors and homocysteine as risk factors for thrombosis in hypercholesterolemia?

Methods: In this experimental study, 60 patients (30 men and 30 women with a mean age of 40- 70 years) diagnosed with hypercholesterolemia (cholesterol > 250 mg/dl) participated in this research. 30 patients were prescribed rosuvastatin (20 mg/day), and 30 patients were simultaneously taken placebo for three months. All parameters, including FVIII, FV, Fibrinogen, DDimer, plasma homocysteine level and lipid profile, were measured before and after treatment. All the results were statistically compared between the two groups.

Results: In patients who took rosuvastatin, the drug was able to significantly reduce the concentrations of total cholesterol, triglycerides, and low-density lipoprotein (LDL) (P < 0.001). Also, rosuvastatin was able to reduce the concentrations of homocysteine significantly, D-Dimer (P < 0.001), coagulation factor VIII and factor V (P < 0.05). In patients with hypercholesterolemia who took the placebo, did not affect the mentioned variables (P > 0.05).

Conclusion: According to the results, it seems that rosuvastatin may be able to reduce the risk of thrombosis in patients by affecting coagulation factors and homocysteine levels.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cardio-metabolic Disorders Affected by Genetic Polymorphisms Related to Premature Menopause. Factor Xa Inhibitors and Low Molecular Weight Heparins in Perioperative Surgical Thromboprophylaxis: A Network Meta-Analysis. Iron Deficiency and its Relationship with Chronic Heart Failure- A Review. Sodium Butyrate, a Gut Microbiota Derived Metabolite, in Type 2 Diabetes Mellitus and Cardiovascular Disease: A Review. The Effect of CD31 on Coronary Collateral Development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1